We have located links that may give you full text access.
FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential.
Nuclear Medicine Communications 2010 June
OBJECTIVE: We retrospectively evaluated the relationships between primary tumor F-fluorodeoxyglucose (FDG) uptake measured as the maximum standardized uptake value (SUV(max)) and local extension, and nodal or distant metastasis in patients with cervical cancer on pretreatment FDG positron emission tomography-computed tomography (PET-CT).
METHODS: Forty-three patients (mean age, 55.14 years; range, 34-90 years) with cervical cancer who underwent FDG PET-CT scans for staging before the initiation of treatment were included in the study. Primary tumor SUV(max) was calculated; clinical tumor stages, presence of local extension, sites of lymph node and distant organ metastases were recorded. The patients were divided into low and high SUV groups by using the median primary tumor SUV(max). The low SUV group consisted of 21 patients with SUV(max) less than 13.5, the high SUV group consisted of 22 patients with SUV(max) > or = 13.5. Their data were compared statistically.
RESULTS: The average SUV(max) was 9.6+/-2.6 and 19.9+/-4.9 in the low and high SUV groups, respectively. In the low SUV group, six patients (29%) had a local extension, eight (38%) had pelvic and/or para-aortic lymph node metastasis, and one had distant organ metastasis (4.7%). In the high SUV group, 10 patients (45%) had a local extension, 16 (73%) had pelvic and/or para-aortic lymph node metastasis, and two (9%) had distant organ metastases. There was a significant difference in the lymph node metastasis rate between the two groups (P<0.05), but differences in local extension and distant organ metastasis were not statistically significant (P>0.05). In addition, there was a moderate correlation between SUV(max) and clinical tumor stages (r=0.40, P=0.0075).
CONCLUSION: Higher primary tumor FDG uptake predicts higher nodal metastatic potential in cervical cancer patients. Patients with higher SUV(max) in cervical tumor may need a close follow-up because of their higher metastatic potential.
METHODS: Forty-three patients (mean age, 55.14 years; range, 34-90 years) with cervical cancer who underwent FDG PET-CT scans for staging before the initiation of treatment were included in the study. Primary tumor SUV(max) was calculated; clinical tumor stages, presence of local extension, sites of lymph node and distant organ metastases were recorded. The patients were divided into low and high SUV groups by using the median primary tumor SUV(max). The low SUV group consisted of 21 patients with SUV(max) less than 13.5, the high SUV group consisted of 22 patients with SUV(max) > or = 13.5. Their data were compared statistically.
RESULTS: The average SUV(max) was 9.6+/-2.6 and 19.9+/-4.9 in the low and high SUV groups, respectively. In the low SUV group, six patients (29%) had a local extension, eight (38%) had pelvic and/or para-aortic lymph node metastasis, and one had distant organ metastasis (4.7%). In the high SUV group, 10 patients (45%) had a local extension, 16 (73%) had pelvic and/or para-aortic lymph node metastasis, and two (9%) had distant organ metastases. There was a significant difference in the lymph node metastasis rate between the two groups (P<0.05), but differences in local extension and distant organ metastasis were not statistically significant (P>0.05). In addition, there was a moderate correlation between SUV(max) and clinical tumor stages (r=0.40, P=0.0075).
CONCLUSION: Higher primary tumor FDG uptake predicts higher nodal metastatic potential in cervical cancer patients. Patients with higher SUV(max) in cervical tumor may need a close follow-up because of their higher metastatic potential.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app